公司名稱:南京康佰生物科技有限公司
地址:南京市雨花區長虹路222號
郵編:
電話:025-86880024
手機: 18066071954
聯系人: 蔣
傳真:
E-mail: duhaitao@cobioer.com
地址:南京市雨花區長虹路222號
郵編:
電話:025-86880024
手機: 18066071954
聯系人: 蔣
傳真:
E-mail: duhaitao@cobioer.com
CBP60789I 2.1人急性淋巴細胞白血病細胞的詳細資料:
I 2.1人急性淋巴細胞白血病細胞
CBP60789 | |
I. General information | |
Synonyms: | I 2.1 |
Background: | The I 2.1 cell line is a FADD mutant of the wild-type Jurkat cell line A3 see ATCC -CRL-2570. Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. Ref ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. Ref Two of these ICR-191 treated clones have been deposited at the ATCC . They are I 9.2 ATCC CRL-2571, a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2.1 ATCC CRL-2572, a clone with a mutation in the adaptor FADD. |
Species: | Homo sapiens, human |
Disease: | acute T cell leukemia |
Gender: | male |
Morphology: | lymphoblast |
Growth Mode: | suspension |
DNA Profile: | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 8,11 D16S539: 11 D5S818: 9 D7S820: 8,10 THO1: 6,9.3 TPOX: 8,10 vWA: 17,18 Cobioer’s Cell Line Authentication Service |
Culture Medium: | RPMI-1640+15%FBS We strongly suggest to purchase the complete medium from Cobioer. |
Cryopreservation medium: | 90%FBS+10%DMSO |
Comments: | Unlike the parental line A3 that does express FADD, the I 2.1 cell line does not express FADD protein by immunoblot analysis and is completely resistant to Fas-induced death. Complementation of the I 2.1 cell lines with wild-type FADD restores Fas-mediated apoptosis. Fas activation of caspase-2, caspase-3, caspase-7, and caspase-8 is completely defective in the FADD mutant cell line I 2.1. Ref This cell line can be used to study the role of FADD in apoptotic signaling pathways in the absence of overxpression. For more information, please contact Cobioer 4008-750-250. |